TY - CHAP
T1 - Gastrointestinal Tract Adverse Events
AU - Abu-Sbeih, Hamzah
AU - Wang, Yinghong
N1 - Publisher Copyright:
© 2020, Springer Nature Switzerland AG.
PY - 2020
Y1 - 2020
N2 - Immune checkpoint inhibitors (ICIs) have shown significant benefit in cancer patients. Their success, however, is associated with immune-related adverse events (irAEs), which commonly affect the gastrointestinal tract, resulting in diarrhea and colitis. IrAEs range from mild self-limiting to severe life-threatening diseases and potentially limit the use of these medications. Diagnosis of ICI-induced enterocolitis is based on clinical symptoms, physical examination, stool tests, endoscopic and histologic evaluation, and/or imaging. Current management strategy is mainly anti-diarrheal agents for mild symptoms and immunosuppressants (e.g., corticosteroids, and infliximab or vedolizumab) for more severe diseases.
AB - Immune checkpoint inhibitors (ICIs) have shown significant benefit in cancer patients. Their success, however, is associated with immune-related adverse events (irAEs), which commonly affect the gastrointestinal tract, resulting in diarrhea and colitis. IrAEs range from mild self-limiting to severe life-threatening diseases and potentially limit the use of these medications. Diagnosis of ICI-induced enterocolitis is based on clinical symptoms, physical examination, stool tests, endoscopic and histologic evaluation, and/or imaging. Current management strategy is mainly anti-diarrheal agents for mild symptoms and immunosuppressants (e.g., corticosteroids, and infliximab or vedolizumab) for more severe diseases.
KW - Colitis
KW - Diarrhea
KW - Enterocolitis
KW - Gastrointestinal adverse events
KW - Immune checkpoint inhibitors
KW - Immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85083477258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083477258&partnerID=8YFLogxK
U2 - 10.1007/978-3-030-41008-7_12
DO - 10.1007/978-3-030-41008-7_12
M3 - Chapter
C2 - 32301019
AN - SCOPUS:85083477258
T3 - Advances in Experimental Medicine and Biology
SP - 247
EP - 253
BT - Advances in Experimental Medicine and Biology
PB - Springer
ER -